Overview
Updated 14 Jul 2026
David R. Gandara, M.D., is Professor Emeritus of Medicine at UC Davis Comprehensive Cancer Center, Division of Hematology and Oncology (NOT "Comprehensive Blood & Cancer Center" of Bakersfield, CA, independently re-checked: CBCC's own clinical-team roster (cbccusa.com/clinical-team) lists Ravi Patel, Neal Ammar, Sherif Ammar, Geover Fernandez, David Hsiang, and Kalyan Gaddam, with no Gandara at all. That seed institution is confirmed unrelated to this individual.). The public record shows 1,114 publications with 55,117 citations (h-index 100), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 37 companies, 7 NIH-funded awards (1997–2025).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 37 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 466.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Sponsor: SWOG Cancer Research Network
InvestigatorPhase 2RecruitingNCT06116682 - Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Sponsor: SWOG Cancer Research Network
InvestigatorPhase 2RecruitingNCT06031688 - Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Sponsor: SWOG Cancer Research Network
InvestigatorPhase 2RecruitingNCT05642572
Industry payments
Updated 14 Jul 2026
37 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202516 payments$18,363openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202511 payments
- IMMUNITYBIO, INC.Program year20251 payment
NIH funding
Updated 14 Jul 2026
7 NIH research awards on record, funded 1997–2025 per NIH RePORTER. The latest:
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Authors response to "Letter to the Editor": "Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types".
Journal for immunotherapy of cancer
2025
Most-cited worksby citation count (OpenAlex)
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physicians.ucdavis.edu ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗
- Editor-in-Chief
Clinical Lung Cancer journal; serves on editorial boards of multiple oncology journals
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →giantsofcancercare.com ↗
Secondary affiliationsappointments beyond the home institution
- Adjunct Clinical Professor
Translational and Clinical Research Program, University of Hawaii Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗ - Co-Director
Center for Experimental Therapeutics in Cancer, UC Davis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗ - Chief Medical Officer
International Society for Liquid Biopsy (ISLB)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- X / Twitter
x.com/drgandara
- LinkedIn
linkedin.com/in/david-gandara-md-361b55123
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by otherswhere others cite or feature them
- Other
health.ucdavis.edu/cancer/team/292/david-gandara---cancer---hematology-oncology---internal-medicine-sacramento
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗ - Other
iaslc.org/iaslc-news/lung-cancer-considered/blood-based-testing-and-evolution-lung-cancer-dr-david-gandara
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗ - LinkedIn
LinkedIn: "David Gandara, MD - Professor at UC Davis Comprehensive Cancer Center" (auth-walled; independently corroborated by two separate SERP passes matching institutional affiliation, title, and IASLC role)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pasi Janne, MD, PhD
Harvard University
- 2,385
- publications
- 163
- h-index
- 15
- trials
Julie Brahmer, MD
Bloomberg (United States)
- 855
- publications
- 116
- h-index
- 12
- trials
Enriqueta Felip, MD, PhD
Hebron University
- 1,460
- publications
- 129
- h-index
- 8
- trials
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
- 2,643
- publications
- 148
- h-index
- 8
- trials